Science

Earnings on the Doorstep For Sangamo Therapeutics, Inc

(SGMO) by 9.22% based on its latest 2017Q2 regulatory filing with the SEC. The score helps determine if a company's stock is valuable or not. Zacks Investment Research raised shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research report on Friday, August 18th.

Depending on the earnings numbers reported, Sangamo Therapeutics, Inc. The recent change has given its price a 15.2% lead over SMA 50 and -2.74% deficit over its 52-week high. About 447,431 shares traded.

The market experts are predicting a 72.37% rally, based on the high target price ($76) for Micron Technology, Inc. shares that is likely to be hit in the 52 weeks. It has outperformed by 13.08% the S&P500. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The hedge fund run by Philippe Laffont held 12.57M shares of the consumer services company at the end of 2017Q2, valued at $492.98M, down from 12.66M at the end of the previous reported quarter. The stock rose 1.94% or $0.77 reaching $40.56. Given that liquidity is king in short-term, SGMO is a stock with 83.61 million shares outstanding that normally trades 9.1% of its float. These holdings make up 63.88% of the company's outstanding shares. Therefore 81% are positive.

According to Finviz reported data, The SMA20 of the stock is at -4.06%, SMA50 is -1.81 percent, while SMA200 is 4.19%. The firm has "Buy" rating by Jefferies given on Thursday, June 22. The company was downgraded on Wednesday, October 19 by PiperJaffray. The company's market capitalization is $218.93 million.

This article was originally published by and is the sole property of American Banking News. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

In terms of earnings per share, 5 analysts have a -0.22 EPS mean target for the quarter ending Dec-17, for the quarter ending Mar-18, 4 analysts have a -0.23 EPS mean target and for the quarter ending Mar-18 there are 5 estimates of -0.82 EPS. If the ratio is greater than 1, then that means there has been an increase in price over the month. Its up 0.79, from 0.8 in 2017Q1. It improved, as 13 investors sold SGMO shares while 31 reduced holdings. BlackRock Fund Advisors raised its position in Sangamo BioSciences by 5.7% in the third quarter. Fic Capital holds 3.48% or 960,338 shares in its portfolio. SGMO has a beta of 3.06 and RSI is 38.14. Altrinsic Global Advsrs Llc holds 0.18% or 580,000 shares. Sangamo Therapeutics earned a media sentiment score of 0.20 on Accern's scale. Meeder Asset Mngmt accumulated 592 shares. Frontier Capital Mngmt Ltd Company owns 495,028 shares. Bogle Investment Mgmt LP De holds 394,877 shares.

Shares of Sangamo BioSciences (NASDAQ:SGMO) traded up 1.64% during mid-day trading on Tuesday, reaching $3.10. Baldwin Brothers Inc Ma owns 1,500 shares. Its down 5.1% from 8.06 million shares, reported previously. Geode Cap Ltd Liability Com has 727,615 shares.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. Eam Invsts Lc has invested 0.16% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO). Sangamo Biosciences had 17 analyst reports since August 8, 2015 according to SRatingsIntel. Investors may also use shareholder yield to gauge a baseline rate of return. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued. The rating was maintained by JP Morgan on Thursday, September 3 with "Buy". The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has "Buy" rating given on Friday, October 13 by Jefferies. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has "Buy" rating given on Wednesday, September 2 by Jefferies. The rating was maintained by Wedbush with "Buy" on Wednesday, September 2. The company was maintained on Saturday, August 8 by JP Morgan. Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the company a "hold" rating in a report on Thursday, August 10th. On Tuesday, November 1 the stock rating was downgraded by Wedbush to "Neutral".



Like this

Latest


10 November 2017
BMO Capital Sticks to Their Hold Rating for Pacira Pharmaceuticals
The total amount of shares outstanding is 40.16 million, giving the company a market capitalization of about 1.65 billion. Looking at some more average volume numbers, the 20 day is 913020, and the 50 day average volume is noted as 706470.

10 November 2017
FBI Investigates Supervisor, Missing Handgun, After July Theft At Charlotte Hotel
He was at the Westin Hotel in Charlotte for a conference this summer when the theft was reported to the local police. Police believe the theft happened sometime between 2 and 5am - after the hotel bar was closed.

10 November 2017
Germany boss Joachim Loew: England are no longer the long-ball country
"Some players, like Toni Kroos and Mats Hummels , are integral parts of our set-up if they are injury-free", added Low. It's a period of testing and is a test run for some players.

10 November 2017
ICC approves investigation into crimes against humanity in Burundi
The alleged acts of violence have reportedly resulted in the displacement of 413,490 persons between April 2015 and May 2017. Other African nations have made similar complaints, with both Gambia and South Africa having threatened to leave.

10 November 2017
Here's Daimler's First All-Electric School Bus
Thomas Built Buses , a subsidiary of Daimler , has introduced the Saf-T-Liner C2 Electric Bus that has earned the nickname "Jouley".

10 November 2017
The Montag & Caldwell LLC Takes Position in Danaher Corp. (DHR)
Bedrijfstakpensioenfonds Voor De Media Pno holds 0.29% of its portfolio in Danaher Corporation (NYSE: DHR ) for 29,437 shares. Cypress Asset Management Inc decreased Intel Corp (NASDAQ:INTC) stake by 20,616 shares to 109,425 valued at $3.69M in 2017Q2.

10 November 2017
Iconix Brand Group (ICON): What Are the Signals Showing?
For shareholders, given the total diluted outstanding shares of 57.08 million, this means overall earnings per share of -1.08. Pub Employees Retirement Association Of Colorado holds 0.01% of its portfolio in Bunge Ltd (NYSE:BG) for 26,775 shares.

10 November 2017
FY2019 EPS Estimates for Medtronic PLC Cut by Oppenheimer Holdings (MDT)
The Schafer Cullen Capital Management Inc holds 3.76 million shares with $169.35 million value, up from 3.55M last quarter. BidaskClub lowered Medtronic PLC from a "hold" rating to a "sell" rating in a research report on Saturday, August 26th.

10 November 2017
Total System Services, Inc
Several other large investors have also modified their holdings of the company. 62 funds opened positions while 150 raised stakes. The stock has a market cap of $13,570.97, a PE ratio of 23.46, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11.

10 November 2017
Turkish and U.S. defense ministers to discuss regional issues
Turkish National Defense Minister Nurettin Janikli will discuss regional issues with US Defense Secretary James Mattis. The two leaders met to reaffirm the longstanding defense relationship between the United States and Turkey, she said.



Recommended